Gliclazide - Revisiting a Preferred Sulphonylurea in 2025 - Dr Silima Tarenia and Dr Shehzad Ruman
Written By : Dr Silima S Tarenia
Written By : Dr Shehzad Ruman
Written By : Dr. Nandita Mohan
Published On 2025-11-13 12:30 GMT | Update On 2025-11-13 12:30 GMT
Advertisement
On this World Diabetes Day, we bring you a special episode of Dia Dialogues titled "Gliclazide - Revisiting a Preferred Sulphonylurea in 2025."
In this discussion, Dr Silima Tarenia, Endocrinologist from Kolkata, and Dr Shehzad Ruman, Endocrinologist from Hyderabad, share their expert insights on the evolving role of modern sulphonylureas (SUs) in type 2 diabetes (T2D) management.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.